5. Toxicology Studies

5.1. Repeated-Dose Toxicity

The repeated-dose toxicity studies in animals are designed to include a similar or longer exposure time than in human studies. As shown in Table 2, repeated-dose toxicity studies in two species (one non-rodent) for at least two weeks would generally support any clinical trial of up to two weeks. Clinical trials of more than two weeks should be supported by repeated-dose toxicity studies of at least the same duration. Six-months rodent and nine-months non-rodent studies generally support treatment for more than six months in clinical trials.

Maximum Duration of Clinical Trial

Recommended Minimum Duration of Repeated-Dose Toxicity Studies to Support Clinical Trials


Rodents

Non-rodents

Up to 2 weeks

2 weeksa

2 weeksa

Between 2 weeks and 6 months

Same as clinical trialb

Same as clinical trialb

Longer than 6 months

6 monthsb,c

9 monthsb,c,d

a In the United States, extended single-dose toxicity studies can replace two week studies to support single-dose human trials.

b In some circumstances, clinical trials longer than three months can start, if data are available from a 3-months rodent and a 3-months non-rodent study. On a case-by-case basis, this extension can be supported by chronic, in-life and necropsy data.

c There can be cases where children are the primary population, and where existing animal studies have identified developmental concerns. In these cases, it can be appropriate to do long-term toxicity testing in juvenile animals.

d In the  EU, studies in non-rodents for six months are considered acceptable. However, where studies with a longer duration have been conducted, it is not appropriate to conduct an additional study of six months.

Table 2: Recommended duration of repeated-dose toxicity studies to support the conduct of clinical trials. Table adapted from ICH (2009) M3(R2).

The recommended durations of repeated-dose toxicity studies needed to support a marketing authorisation application (MAA) are shown in Table 3 below.

Duration of Indicated Treatment

Rodent

Non-Rodent

Up to 2 weeks

1 month

1 month

More than 2 weeks to 1 month

3 months

3 months

More than 1 month to 3 months

6 months

6 months

More than 3 months

6 monthsa

9 monthsa,b

a There can be cases where children are the primary population, and where existing animal studies have identified developmental concerns. In these cases, it can be appropriate to do long-term toxicity testing in juvenile animals b In the EU, studies in non-rodents for six months are considered acceptable. However, where studies with a longer duration have been conducted, it is not appropriate to conduct an additional study of six months.

Table 3: Recommended duration of repeated-dose toxicity studies to support an MAA. Table adapted from ICH (2009) M3(R2).

Testing in both rodent and non-rodent animals is important to obtain as much data as possible on toxicity for a given medicine. Each "animal type" has features that can be transposed into human situations and that can help researchers understand the potential toxic effect of the medicine in humans.